Biotechnology CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease June 13, 2022
Biotechnology ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AXSM June 12, 2022
Biotechnology SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation – BPMC June 11, 2022
Biotechnology CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT(TM)-LYM Trial of CTX130(TM) in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress June 11, 2022
Biotechnology The Gross Law Firm Announces Class Actions on Behalf of Shareholders of XRAY, AXSM and IONQ June 10, 2022
Biotechnology Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Shareholders to Contact the Firm June 10, 2022
Search
Biotechnology
